泊沙康唑对临床来源接合菌的体外抗菌活性研究

中国真菌学杂志　 2012, Vol. 7 　Issue (3): 142-145.

泊沙康唑对临床来源接合菌的体外抗菌活性研究

王思卜, 万喆, 李若瑜, 余进

北京大学第一医院皮肤科北京大学真菌与真菌病研究中心,北京 100034

收稿日期:2011-12-08 出版日期:2012-06-28 发布日期:2012-06-28
通讯作者: 余进,E-mail:yujin676@gmail.com E-mail:yujin676@gmail.com
作者简介:王思卜,女 (汉族),硕士研究生在读.E-mail:mengbo2274@sina.com
基金资助:
卫生部部属 (管)医院2010-2012年度临床学科重点项目基金 (2010-2012),2010-2012年度杨森科学研究委员会中国分会研究基金 (2010-2012)

In vitro activity of posaconazole against 43 clinical isolates of zygomycetous fungi by E-test

WANG Si-bu, WAN Zhe, LI Ruo-yu, YU Jin

Department of Dermatology,Peking University First Hospital,Research Center for Medical Mycology,Peking University,Beijing 100034,China

Received:2011-12-08 Online:2012-06-28 Published:2012-06-28

摘要/Abstract

摘要： 目的研究泊沙康唑对临床来源的接合菌体外抗菌活性。方法对临床来源的43株接合菌采用ITS区序列分析进行准确鉴定,采用E-test纸片法研究泊沙康唑对43株菌的体外药物敏感性,观察其MIC值。结果经ITS序列分析鉴定,43株临床来源接合菌中最为常见的是小孢根霉和不规则毛霉 (各12株),其次为米根霉 (10株),ramosa (3株)。其他菌种分别为ornata、总状共头霉、微小根毛霉、卷曲毛霉、印度毛霉和冻土毛霉各1株。E-test纸片法测得泊沙康唑对毛霉属、根霉属和Lichtheimia spp.的MIC值范围分别为0.19~>32 μg/mL、0.19~3 μg/mL、0.002~0.38 μg/mL,对总状共头霉和微小根毛霉的MIC值分别为1 μg/mL和0.19 μg/mL。结论泊沙康唑对大部分接合菌有效,不同种属MIC值范围不同,毛霉属真菌的MIC值差异较大。

关键词: 泊沙康唑, E-test纸片法, 接合菌

Abstract: Objective To investigate the in vitro acvtivity of posaconazole against 43 clinical isolates of zygomycetous fungi.Methods Forty-three clinical strains were re-identified by ITS region sequencing. The minimal inhibitory concentration of posaconazole against 43 clinical isolates of zygomycetous fungi was assayed by E-test.Results Forty-three strains included Rhizopus microsporus (12 isolates),Mucor irregularis (12 isolates),R.oryzae (10 isolates),Lichtheimia ramosa (3 isolates),L.ornata (1 isolate),Syncephalastrum racemosum (1 isolate),Rhizomucor pusillus (1 isolate),M.circinelloides (1 isolate),M.indicus (1 isolate) and M.hiemalis ( 1 isolate). The MIC ranges of posconazole against Mucor spp.,Rhizopus spp. and Lichtheimia spp. in E-test were 0.19->32 μg/mL, 0.19-3 μg/mL and 0.002-0.38 μg/mL, respectively. The MIC values of posaconazole against Syncephalastrum racemosum and Rhizomucor pusillus were 1 μg/mL and 0.19 μg/mL, respectively.Conclusion Most isolates of zygomycetous fungi were susceptible to posaconazole. The MIC values of Mucor spp. were relatively variable.

Key words: posaconazole, E-test, Zygomycetous fungi

中图分类号:

R 379.9

王思卜, 万喆, 李若瑜, 余进. 泊沙康唑对临床来源接合菌的体外抗菌活性研究[J]. 中国真菌学杂志, 2012, 7(3): 142-145.

WANG Si-bu, WAN Zhe, LI Ruo-yu, YU Jin. In vitro activity of posaconazole against 43 clinical isolates of zygomycetous fungi by E-test[J]. Chinese Journal of Mycology, 2012, 7(3): 142-145.

参考文献

[1] Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases[J]. Clin Infect Dis, 2005, 41(5): 634-653.
[2] Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease[J]. Clin Microb Rev, 2000, 13(2): 236-301.
[3] Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal[J]. Lancet Infect Dis, 2005, 5(12): 775-785.
[4] Rodríguez, MM, Serena C, Mariné M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae[J]. Antimicrob Agents Chemother, 2008, 52(10): 3786-3788.
[5] Sun QN, Najvar LK, Bocaneqra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model[J]. Antimicrob Agents Chemother, 2002, 46(7): 2310-2312.
[6] Kontoyiannis DP, Lewis RE. How I treat mucormycosis[J]. Blood, 2011, 118(5):1216-1224.
[7] 王思卜,张杰,余进等. 用ITS和TUB序列差异鉴定临床相关波氏假阿利什霉/尖端赛多孢[J]. 中华检验医学杂志,2012,12(34): 1084-1087.
[8] Barry AL, Pfaller MA, Brown SD, et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents[J]. J Clin Microbiol, 2000, 38(9):3457-3459.
[9] lvarez E, Cano J, Stchiqel AM, et al. Two new species of Mucor from clinical samples[J]. Med Mycol, 2011, 49(1):62-72.
[10] Schell WA, O'Donnell K,Alspaugh JA. Heterothallic mating in Mucor irregularis and first isolate of the species outside of Asia[J]. Med Mycol, 2011, 49(7): 714-723.
[11] Alastruey-Izquierdo A, Hoffmann K, de Hoog GS, et al. Species recognition and clinical relevance of the Zygomycetous genus Lichtheimia (syn. Absidia Pro Parte, Mycocladus)[J].J Clin Microbiol, 2010, 48(6) : 2154-2170.
[12] Almyroudis NG, Sutton DA, Fothergill AW, et al.In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents[J]. Antimicrob Agents Chemother,2007, 51(7): 2587-2590.
[13] Sun QN, Fothergill AW, McCarthy DI, et al.In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes[J]. Antimicrob Agents Chemother, 2002, 46(5): 1581-1582.
[14] Torres-Narbona M,Guinea J,Martinez-Alarcon J,et al.In vitro activities of amphotericin B,caspofungin,itraconazole,posaconazole,and voriconazole against 45 clinical isolates of zygomycetes:comparison of CLSI M38-A,Sensititre YeastOne,and the Etest[J].Antimicrob Agents Chemother,2007,51(3):1126-1129.